SNN administration could improve the lipid metabolism disorder and liver damage of NAFLD, and the regulation of the SIRT1/AMPK signaling pathway may contribute to the underlying mechanism. Here, SIRT1 is linked to metabolic dysfunction-associated steatotic liver disease.